Latest news
Actimed regains global rights to S-oxprenolol - The Pharma LetterThe Pharma Letter · Thu, 06 Aug 2026 13:52:58 GMTActimed gets back rights to wasting disease drug, ending $126M deal with Faraday - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 12:20:19 GMTActimed retrieves ALS drug after Faraday collapse - European Biotechnology MagazineEuropean Biotechnology Magazine · Thu, 06 Aug 2026 12:13:31 GMTActimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline Opportunity - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 07:15:12 GMTActimed strengthens board with appointment of Dr Anders Ullman - Manufacturing ChemistManufacturing Chemist · Thu, 30 Jul 2026 13:03:34 GMT